Merck & Company Inc (MRK) Shares Outstanding 2006–TTM

Name: Merck & Company Inc (MRK) shares outstanding history 2006-TTM
Creator: TickerBase

DATA UPDATED 2026-07-12

Merck & Company Inc annual shares outstanding for fiscal TTM was 2,472 million shares, a decrease of 1.4% from 2,507 million shares in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

MRK Annual Shares Outstanding

Shares Outstanding (annual)	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Shares Outstanding (M)	2,472M	2,507M	2,541M	2,547M	2,542M	2,538M	2,541M	2,580M	2,679M	2,748M	2,787M	2,841M	2,928M	2,996M	3,076M	3,094M	3,120M	2,273M	2,143M	2,193M	2,188M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MRK Quarterly Shares Outstanding

Shares Outstanding (quarterly)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Shares Outstanding (M)	2,472M	2,488M	2,498M	2,513M	2,531M	2,541M	2,541M	2,544M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

More MRK metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Free Cash Flow

All MRK financial statements → Interactive MRK charts →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.